Sex Differences in a Contemporary, Real-World Cohort of Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis

Loading...
Thumbnail Image

Identifiers

Publication date

Authors

Fontana, Marianna
Aimo, Alberto
Grogan, Martha
Maurer, Mathew S.
Siepen, Fabian aus dem
Hanna, Mazen
Delgado, Diego
Carlsson, Martin
Damy, Thibaud

Advisors

Other responsabilities

Journal Title

Bibliographic citation

Fontana M, Aimo A, Grogan M, Crespo-Leiro MG, Maurer MS, Siepen FAD, Hanna M, Delgado D, Carlsson M, Damy T, Davis MK. Sex differences in a contemporary, real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis. Cardiol Ther. 2026 Oct;15(Suppl 1):81-93.

Type of academic work

Academic degree

Abstract

[Abstract] Introduction: Tafamidis improves outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) versus placebo. ATTR-CM has historically been considered a predominantly male disease, and women are underrepresented in prior studies. Sex-specific data in contemporary patients treated with tafamidis remain limited. Methods: Data from two cohorts were pooled: an early-access cohort (NCT02791230) and patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS; NCT00628745) in 2019-2023. This analysis evaluated sex-related differences in clinical characteristics and all-cause mortality, adjusting for age, cohort, baseline New York Heart Association (NYHA) class, and wild-type (ATTRwt-CM) versus variant (ATTRv-CM) disease. Results: Overall, 1924 patients treated with tafamidis were included (1476 from the early-access cohort and 448 from THAOS), of whom 214 (11.1%) were women. A smaller proportion of women than men had ATTRwt-CM (59.8% vs. 88.9%), whereas a greater proportion had ATTRv-CM (40.2% vs. 11.1%; p < 0.0001). Women were more frequently of African descent (23.9% vs. 7.4%; overall p < 0.001). Age at enrollment, age at symptom onset, and time from symptom onset to diagnosis were similar between sexes (p > 0.05). Women appeared more symptomatic at baseline, with a higher proportion in NYHA class III/IV (37.7% vs. 29.4%; overall p = 0.036) and classified as National Amyloidosis Centre stage II/III (68.1% vs. 47.7%; overall p = 0.023), despite similar N-terminal pro-B-type natriuretic peptide levels (p > 0.05). In adjusted analyses, women had a higher estimated glomerular filtration rate than men (β [men vs. women] = - 10.61; p < 0.001). Over a mean follow-up of 1.5 years, men had a higher risk of all-cause mortality than women (adjusted hazard ratio [men vs. women], 1.60, 95% CI 1.12-2.30). Conclusions: In this analysis of contemporary patients with ATTR-CM treated with tafamidis, women represented a small proportion of the overall population, and a greater proportion had ATTRv-CM compared with men. Although women appeared more symptomatic at presentation, men had a higher risk of all-cause mortality.

Description

Brief report

Rights

Attribution-NonCommercial 4.0 International
Attribution-NonCommercial 4.0 International

Except where otherwise noted, this item's license is described as Attribution-NonCommercial 4.0 International